IMPORTANCE Depressive disorders (DDs), anxiety disorders (ADs), obsessive-compulsive disorder (OCD), and posttraumatic stress disorder (PTSD) are common mental disorders in children and adolescents.
D epressive disorders (DDs), anxiety disorders (ADs), obsessive-compulsive disorder (OCD), and posttraumatic stress disorder (PTSD) are among the most common mental disorders in children and adolescents. 1 They are major public health concerns and predict long-term risk for various adverse outcomes. 2 Thus, early diagnosis and proper treatment is of critical importance. Selective serotonin reuptake inhibitors (SSRIs) are first-line pharmaceutical treatments for these disorders, whereas serotonin-norepinephrine reuptake inhibitors (SNRIs) are considered second-or third-line treatments, given the limited available trial data to support their use. 3 This meta-analysis compares the differential efficacy of these drugs across the disorders for which they are primarily prescribed in a pediatric population and also assesses differences in response to placebo and in adverse events.
Since the release of fluoxetine hydrochloride in the mid1980s, the number of SSRIs and SNRIs has grown substantially. However, their use in children and adolescents is still debated, thus indicating a need for more research into their safety and efficacy and the comparative efficacy of the newer SNRIs vs SSRIs. 4 Recent meta-analyses generate many questions about the overall benefits vs costs of using SSRIs to treat major depression in children and adolescents. 5 The small amount of research on SNRIs for pediatric DD has had mixed results. 3 One meta-analysis on pediatric depression found that, although SSRIs differed significantly from placebo, SNRIs and tricyclic antidepressants did not. 6 Although most prior reviews and meta-analyses of the effects of SSRIs and SNRIs focused on pediatric DD, considerable data also exist on pediatric AD and OCD. The latter studies suggest that most SSRIs have a favorable risk-benefit ratio, whereas there are insufficient data for the remaining SSRIs. 3 There have been relatively few studies on SNRIs for pediatric AD, despite the fact that the only US Food and Drug Administration (FDA)-approved agent for pediatric AD, duloxetine hydrochloride, is an SNRI. To our knowledge, no double-blind, randomized clinical trials of SNRIs for pediatric OCD had been conducted as of 2016, and limited data have been reported for SSRIs and SNRIs in pediatric PTSD. 7 Research on safety and tolerability indicates a high risk of developing treatment-emergent adverse events (TEAEs)-most prominently headache and nausea-during treatment with an antidepressant in pediatric DD. 6 Severe adverse events (SAEs), such as an increased risk of suicidal thoughts and behavior, in adults and youth receiving antidepressants have also been reported, 8 leading to the implementation of a boxed warning on the labels of all antidepressants for pediatric use by the FDA in 2004, although adoption of the warning remains controversial. 9 In addition, to date no recent meta-analyses have focused on how pediatric adverse effect profiles of SSRIs, SNRIs, and placebo might differ across disorders. Finally, there is a growing body of literature concerning the role of placebo effects in studies of SSRIs and SNRIs, based on large placebo responses in studies of antidepressants in both adult and pediatric samples. 10 Factors such as contact with research staff may lead to large placebo response rates in pediatric DD 11 and may explain much of the variability in pediatric antidepressant trials. 12 For adults with DD, a genuine placebo effect has been demonstrated, as the combination of placebo and supportive care has been shown to be more beneficial than supportive care alone. 13 Conversely, patients in the placebo group also demonstrate TEAEs. 6 However, how response to placebo differs across disorders or other study design features in pediatrics remains understudied.
To our knowledge, only 1 other review or meta-analysis has examined the use of SSRIs and SNRIs across pediatric DD, AD, OCD, and PTSD. 14 However, that earlier study is now a decade old and predates 11 primary studies (n = 2068) that fulfill our inclusion criteria. The earlier review also did not include any studies on duloxetine, which is currently the only medication approved for pediatric AD. We therefore conducted an updated and extended review to assess the efficacy and safety of these drugs for treatment of DD, AD, OCD, and PTSD, along with betweendisorder variation in drug and placebo responses. Psychological therapies are not part of this meta-analysis. However, a more recent review has compared psychological therapies alone and in combination with antidepressant medication for depression in children and adolescents. 15 
Methods

Search Strategy and Study Selection
The study was conducted in accordance with the PRISMA statement. 16, 17 We searched PubMed, EMBASE, PsycInfo, Cochrane, and Web of Science from inception until August 7, 2016;  clinicaltrials.gov; and fda.gov and checked references of the included studies as well as previous reviews. Additional information on search terms is presented in the eAppendix 1 in the Supplement. In total, this search returned 4899 articles (eFigure 1 in the Supplement). The screening and selection process was conducted independently by 3 of us (C.L., H.K., and S.R.Z.). We included randomized, double-blind, placebocontrolled trials of SSRIs and SNRIs in children and adolescents younger than 18 years, including studies that examined drug vs placebo, both in the context of a psychosocial intervention, in which case the combination group was extracted only if no comparison of drug and placebo alone was given. Participants were required to have a diagnosis of a DD, AD, OCD, or PTSD, based on DSM-III, DSM-III-R,orDSM-IV-TR criteria. Comorbidity was allowed, and information about comorbid disorders was extracted. Case reports, comments, letters, gray literature, and reviews were excluded. Non-second-generation antidepressants (eg, monoamine oxidase inhibitors, tricyclic antidepressants) were also excluded. 18 Boston Children's Hospital provided approval for the study.
Methodologic Quality Assessment
Two of us (C.L. and S.R.Z.) independently rated the quality of included studies based on the Cochrane Risk of Bias Assessment Tool, 19 with final quality ratings based on consensus. Risk of bias was assessed in individual studies (eTable 1 in the Supplement) and across studies (eFigure 2 in the Supplement).
Outcome Measures and Data Extraction
The primary outcome as defined by authors was chosen as the sole outcome measure for each study. Preintervention and postintervention data or mean change data had to be available. Outcomes had to be reported on a well-validated, disorderspecific scale (eg, Children's Depression Rating ScaleRevised, Multidimensional Anxiety Scale for Children, and Children's Yale-Brown Obsessive Compulsive Scale) or on a general severity scale (ie, Clinical Global Impression-Severity Scale). We included only continuous outcome data, since dichotomizing continuous scores into categorical outcome data leads to a loss of information, reduces power, and creates an artificial boundary. 20, 21 We did not extract data from improvement scales, such as the Clinical Global Impression-Global Improvement Scale. Repeated attempts were made to contact the authors of studies with incomplete or insufficient data. Two studies 22, 23 did not include SDs or SEs, and they were imputed by way of the leaving-1-out method. 24 Data were extracted independently by 3 of us (C.L., H.K., and S.R.Z.). Discrepancies were resolved by consensus. Extracted data included demographic information, dropout rates, adverse events, safety information, and baseline and end point assessment points. Data from open-label extensions or follow-up after the predesignated end point were not extracted.
Statistical Analysis
Three effect sizes were calculated for each included study. First, drug-placebo difference response was assessed as the difference in mean change scores between the antidepressants and placebo. The drug and placebo responses were assessed as the mean change scores of preanalyses vs postanalyses in the drug and placebo groups, respectively. Effect sizes were calculated as Hedges g. 25 We chose to use random-effects models rather than fixed-effects models because the studies that we included were heterogeneous and the number of studies for the subanalyses were relatively small. 26 Heterogeneity was assessed by calculating the Q statistic, 27 the τ 2 , and the I 2 , a transformation of Q that indicates the proportion of observed variance that can be attributed to heterogeneity rather than sampling error. 28 The τ 2 offers an estimate of the variance among true effect sizes. 29 Effect size differences between subgroups were analyzed using a mixed-effects model. 30 Publication bias was assessed visually by means of funnel plots 31 and formally by means of the fail-safe N 32 and the Begg adjusted-rank correlation test. 33 We estimated the sensitivity of publication bias, using the trim-and-fill method. 34 Moderator analyses were conducted for 6 continuous moderators (treatment duration, publication year, illness duration, age of onset, number of sites, and baseline severity) and 4 categorical moderators (placebo lead-in, comorbidity, region, and primary funding source). Details of the applied statistical approaches are provided in eAppendix 2 in the Supplement.
To evaluate the risk of adverse events in the antidepressant and placebo groups, risk ratios (RRs) for TEAEs, SAEs, and study discontinuation due to adverse events across trials were calculated in a random-effects model. The RRs of SAEs were based on the percentage of patients with SAEs. Regarding RRs of TEAEs, 2 commonly used reporting methods were compared: percentage of patients with TEAEs in each group and mean number of TEAEs per patient across all reported symptoms. Comprehensive Meta-Analysis, version 3 (Biostat) and R, version 3.2.1 (R Foundation) were used for calculations and analyses.
Results
Our search identified 35 published and 1 unpublished randomized, double-blind trials 7,22,23,35- 18 years with a diagnosis of AD (n = 10), DD (n = 17), OCD (n = 8), or PTSD (n = 1) (eFigure 1 in the Supplement). One study reported 2 trials that were treated independently for analyses 55 and another compared a drug plus psychosocial intervention group vs a placebo plus psychosocial intervention group and was therefore excluded from the drug and placebo response analyses. 59 Characteristics of the 36 included trials are presented in eTable 1 in the Supplement, and details regarding heterogeneity and publication bias can be found in the eTable 2, eAppendix 3, eFigure 2, and eFigure 3 in the Supplement. The combined analysis between groups across all disorders yielded a small drug-placebo difference (g = 0.32; 95% CI, 0.25 to 0.40; P < .001). In the between-group analysis stratified by disorder, AD (g = 0.56; 95% CI, 0.40 to 0.72; P < .001) and OCD (g = 0.39; 95% CI, 0.25 to 0.54; P < .001) did not differ significantly from each other (P = .14), but both yielded significantly higher (AD vs DD: P < .001 and OCD vs DD: P = .02) drug-placebo differences than the DD group (g = 0.20; 95% CI, 0.13 to 0.27; small number of studies and large 95% CI, the effect size for fluvoxamine was not significant. In the between-group analysis stratified by drug category, SSRIs and SNRIs did not differ significantly in the DD group (Q = 0.43 1 ; P = .51), but SSRIs were significantly better than SNRIs in the AD group (Q =4.16 1 ; P = .04). No studies investigated the use of SNRIs in OCD.
The within-drug group analysis stratified by disorder yielded no significant difference (P = .07) between studies of AD (g = 1.68; CI, 1.56-1.79; P < .001) and DD (g = 1.85; 95% CI, 1.7-2.0; P < .001), yet both yielded significantly larger drug responses (P < .001) than studies of OCD (g = 1.01; 95% CI, 0.88-1.14; P < .001). When stratified by drug, duloxetine yielded the largest response (g = 1.95; 95% CI, 1.73-2.18; P < .001) and fluvoxamine the smallest response (g = 1.22; 95% CI, 0.41-2.02; P = .003); however, the difference between those 2 drugs was not significant (Q =3 . 0 2 1 ; P = .08). The combined analysis across all disorders for the within-group analysis yielded a drug response of g =1 . 6 5 (95% CI, 1.52-1.78; P < .001). The SSRIs and SNRIs did not differ significantly in both the DD group (Q =2.35 1 ; P = .13) and the AD group (Q =0.34 1 ; P = .56).
The within-placebo group analysis stratified by disorder yielded a large placebo response for studies of DD (g = 1.57; 95% CI, 1.36-1.78; P < .001), which was significantly larger (P < .001) than the placebo response in studies of AD (g = 1.03; 95% CI, 0.84-1.21; P < .001). The moderate placebo response in the OCD group (g = 0.63; 95% CI, 0.47-0.79; P < .001) was significantly lower than in both the DD (P < .001) and AD (P = .002) groups ( Figure 2) . The combined analysis across all disorders for the within-group analysis yielded a placebo response size of g = 1.23 (95% CI, 1.06-1.39; P < .001).
Adverse Event Analysis
Twenty-six trials reported the percentage of patients with TEAEs (reporting method 1), 26 trials reported the mean number of TEAEs per patient across symptoms (reporting method 2), and 15 trials reported both reporting methods. The 2 reporting methods differed significantly (across all 52 trials: P = .002; within the 15 studies reporting both reporting methods: P = .045), indicating higher RRs with reporting method 2. Patients taking an antidepressant reported significantly more TEAEs (reporting method 1: RR, 1.07; 95% CI, 1.01-1.12; P = .01; reporting method 2: RR, 1.49; 95% CI, 1.22-1.82; P < .001) and SAEs (RR, 1.76; 95% CI, 1.34-2.32; P < .001) compared with placebo. No significant differences in TEAEs or SAEs were found between SSRIs and SNRIs. The RRs for TEAEs stratified by drug and disorder are displayed in Table 1 . Discontinuation of treatment due to adverse events was significantly more common in the antidepressant group compared with the placebo group (RR, 1.79; 95% CI, 1.38-2.32; P < .001). The RRs for study discontinuation and SAEs stratified by drug and disorder are summarized in Table 2 . Mean rates of TEAEs, SAEs, and study discontinuation can be found in eTable 3 in the Supplement.
Moderator Analysis
Univariate analyses indicated larger effect sizes as a function for earlier trials, fewer sites, longer illness duration, and nonindustry funding. However, none of the moderators was found to be significant in a multivariate meta-regression (eAppendix 3 and eTables 4-6 in the Supplement).
Discussion
Our meta-analysis addresses the response and safety profile of SNRIs, SSRIs, and placebo in pediatric DD, AD, OCD, and PTSD. Results indicate that SSRIs and SNRIs are more beneficial than placebo in treating these commonly diagnosed conditions in children and adolescents. However, the overall drugplacebo difference is small and varies significantly by disorder, with a larger response in AD than DD, especially for SSRIs (g = 0.71; 95% CI, 0.45-0.97; P < .001). This difference in drugplacebo difference response is mainly due to a higher placebo response in pediatric DD. Furthermore, patients with OCD exhibit a significantly smaller response to both drug treatment and placebo treatment compared with AD and DD.
The small effect size between SSRIs and SNRIs vs placebo in pediatric DD might be owing to the lack of a clear depression phenotype. This was apparent in DSM-5 field trials on major depressive disorder (MDD), which found a low test-retest reliability (κ = 0.28) for children, adolescents, and adults.
68 Furthermore, there is high comorbidity between pediatric DD and other disorders, especially AD. A recent review on the use of SSRIs and SNRIs in pediatric populations reported that approximately 25% of patients with MDD had a comorbid AD. 3 In our meta-analysis, although not all included studies reported comorbidity rates, those doing so reported comorbidity rates in AD ranging between 6% and 56% in patients with DD. Yet, attempts by the DSM-5 work group to create a "mixed anxiety and depression disorder" resulted in an unacceptable rate of test-retest reliability (κ = −0.004) when tested in the DSM-5 field trials. Because there was only 1 study, posttraumatic stress disorder (PTSD) was not included in subgroup analyses. Responses to selective serotonin reuptake inhibitors (SSRIs) were significantly larger in depressive disorders (DDs) and anxiety disorders (ADs) compared with obsessive-compulsive disorder (OCD) (both P < .001). The placebo response was significantly larger in DDs compared with ADs (P < .001) and OCD (P < .001) and significantly larger in ADs compared with OCD (P < .002). SNRI indicates serotonin-norepinephrine reuptake inhibitor. Although it appears that the response to placebo is robust in pediatric DD, children and adolescents with ADs, who respond to pharmacologic treatment to the same degree as those with DD, do not appear to exhibit such a robust placebo However, because no pediatric trial included a no-treatment arm that could serve as a control for the natural course of the disorders, the difference in placebo response may also reflect differences in the probability of spontaneous improvement between the 2 pediatric disorders rather than differences in the placebo effect. Owing to the small number of studies in children, we could not estimate the drug and placebo response for the individual ADs, yet a recent adult study found drug and placebo effect sizes to be roughly equivalent across ADs. 72 In pediatric patients, however, those with panic disorder seem to experience a greater placebo response compared with patients with generalized AD or social phobia.
73
Our results are very similar to those of a recent metaanalysis of 5 decades of research on youth psychological therapy, 74 which found that mean effect sizes at posttreatment were strongest for AD (g = 0.61), weakest for DD (g = 0.29), and nonsignificant for multiproblem treatment (g = 0.15), indicating a general difficulty in establishing a clinically relevant benefit in the treatment of pediatric depression. The substantial placebo response in MDD indicates that depressed children and adolescents might benefit from innovative treatment modalities that harness the power of the placebo effect in an ethical fashion, including clinician contact 11 and other common factors, such as the patients' expectations of improvement, their desire for relief, and the exposure to treatment rituals. Placebo response also offers several implications for research design in antidepressant trials. Alternative designs, such as a discontinuation design 75 or n-of-1 trials, 
Limitations
Our study has some limitations. First, none of the randomized clinical trials included directly compared effectiveness across disorders. Accordingly, we could only make indirect conclusions with regard to disorder specificity. Second, although our meta-analysis included unpublished trials, reporting bias could lead to an overly positive representation of findings in the literature. 82 In this regard, many concerns have been raised about the accuracy of the data of 1 study in particular: Paxil Study 329. A reanalysis of the original data found that paroxetine did not show efficacy for MDD in adolescents and that the initial study underplayed the drug's potential to increase suicidal thoughts among adolescents. 83 Third, there was variability in the mean age and age distribution between studies, which may have had an effect on results. Response to SSRIs and SNRIs has been shown to be lower in children than in adolescents, in part related to a higher placebo response in children.
14 Fourth, the Begg and Eggers tests 31,33 used to assess publication bias are valid only when there are 10 or more studies being evaluated, and our OCD group consisted of only 8 trials. However, no evidence of publication bias was found in the respective funnel plot. The different reporting methods of adverse events led to subgroup analyses based on only a few studies and should therefore be considered preliminary, requiring further investigation. Furthermore, restrictive inclusion criteria of clinical trials, such as noninclusion of comorbidity and a higher symptom severity threshold, make it difficult to generalize results to real-world populations.
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Finally, because only 1 study met our inclusion criteria for PTSD, 7 no categorical analysis of SSRIs and SNRIs for the treatment of pediatric PTSD was possible.
Conclusions
The main findings of this meta-analysis present multiple avenues for further analyses. First, the nearly identical response rate for pediatric DD and AD deserves further investigation and perhaps the revision of federal prescribing guidelines for these 2 conditions. Although several SSRIs and SNRIs have been approved for the treatment of pediatric DD and OCD, only 1-duloxetine-has recently received FDA approval for treatment of pediatric ADs. 85 Second, the substantial differential response to both drug treatment and placebo treatment in OCD compared with AD and DD highlights underlying differences in the etiologies and pathogeneses of the disorders that may require additional interventions for pediatric patients with OCD. 86 It is our hope that a research domain criteria approach 87 will help to elucidate the abovementioned points and could lead to better treatment outcomes. Third, additional research into the factors that moderate the efficacy of SSRIs and SNRIs in children is warranted, as is the need for more comprehensive reporting of population and illness details (eg, age at onset, duration of illness) in clinical and pragmatic trials. Finally, the significant variability in the assessment and reporting of adverse events highlights the need for a standardized method of reporting TEAEs and SAEs. Given the potential for life-threatening events in young children and adolescents, understanding the extent to which these medications pose a genuine risk to youth is urgent. This need would allow future research to deviate from the current line of studies estimating the magnitude and differences between drug and placebo effects and focus more on precision medicine-driven questions, such as which treatment or combination thereof may be most advantageous for certain patient subgroups in certain clinical settings. 
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Methods and Results for the Univariate Analyses -Continuous Variables
Methods: Moderator analyses were conducted for six continuous moderators (treatment duration, publication year, illness duration, age of onset, number of sites, and baseline severity) for both the combined disorders group and individual disorders groups. We examined whether specific characteristics of the studies were related to the effect sizes (i.e., drug-placebo differences) in univariate analyses. Continuous variables were analyzed with a meta-regression analysis using method-of-moments analyses in a random-effects model. The Z-statistic was used to test the significance of the slope. As various scales were used to assess baseline severity, we standardized the baseline and outcome values by dividing the mean values by the SD.
Results: The relationship between effect size and publication year was significant in the combined analyses (Z=-2.36, p=.02), as well as in the DD subgroup analyses (Z=-2.26, p=.02), with recently published studies yielding smaller antidepressant-placebo differences. Further, the relationship between effect size and illness duration was significant in the combined analyses (Z=2.89, p=.004), indicating that children with a longer duration of illness exhibit greater response to antidepressants compared to placebo. Finally, number of sites was found to be significantly correlated to effect size in the combined analyses (Z=-2.98, p=.003), as well as in the DD subgroup analyses (Z=-2.16, p<.03), and the OCD subgroup analyses (Z=-2.16, p=.03), with number of study sites negatively associated with magnitude of differences between antidepressants and placebo. See eTable 4 for all calculations.
Methods and Results for the Univariate Analyses -Categorical Variables
Methods: Moderator analyses were conducted for four categorical moderators (placebo lead-in, comorbidity, region, and primary funding source) for both the combined disorders group and individual disorders groups. Categorical variables were analyzed using a mixed-effects model We examined whether specific characteristics of the studies were related to the effect sizes (i.e., drug-placebo differences) in univariate analyses.
Results:
The relationship between effect size and primary funding source was significant in the combined analyses (p = .02), as well as in the DD subgroup analyses (p = .02). In both cases, studies that were funded by industry yielded significantly smaller effect sizes than those that reported public sources of funding only (e.g., NIMH). See eTable 5 for further details.
Methods and Results for the Multivariate Metaregression Analysis
Methods: Given the relatively large number of moderator analyses, we decided to conduct a multivariate metaregression. Effect sizes (i.e., dependent variable) were weighted by the sample size divided by s2 (i.e., n/var) This approach is in line with the methods adopted by Cuijpers [2] [3] [4] [5] . The model indicates the significance of each potential moderator while controlling for the others. To avoid collinearity among the predictors of the regression model, we first tested whether high correlations (i.e., correlations higher than 0.60) were found among the moderators that could be entered into the model. Three variables were found to have correlations higher than 0.60: the funding source correlated high with the number of sites (r = .698), treatment duration correlated high with illness duration (r = 0.62), and comorbidity correlated high with the number of sites (r = -0.75). We decided to use the number of sites (not funding source or comorbidity) and illness duration (not treatment duration) as predictors in the model. All remaining variables (i.e., illness duration, publication year, baseline severity, number of sites, age of onset, placebo lead-in, and study location) were included as predictors in the model.
Results: None of the moderators were found to be significant in the multivariate meta-regression with weighted effect sizes. All results can be found in eTable 6. 
